Neuroendocrine Tumor of the Lung
4
1
2
0
Key Insights
Highlights
Treatment Research
7 treatments under study, led by 203lead Pentixather Spectct
Research Leaders
8 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 11 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (4)
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
A Safety Study of 212Pb-Pentixather Radioligand Therapy
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Research Network
Common Treatments
- 203lead Pentixather Spectct1
- 212pb Vmtαnet1
- Everolimus1
- 177ludtpasc16561
- 203pb Vmtαnet Spectct1
Active Sponsors
- National Cancer Institute (NCI)2
- Holden Comprehensive Cancer Center2
- AC Camargo Cancer Center1
- David Bushnell1
- Perspective Therapeutics1
Top Investigators
University of Iowa
Memorial Sloan Kettering Cancer Center
University of Iowa
Related Conditions
- Neuroendocrine Tumor Of Pancreas2
- Neuroendocrine Tumor Grade 12
- Neuroendocrine Tumor Grade 22
- Neuroendocrine Tumors2
- Carcinoma Smallcell Lung1